Cystatins are natural inhibitors of papain-like (family C1) and legumain-related (family C13) cysteine peptidases. Cystatin D is a type 2 cystatin, a secreted inhibitor found in human saliva and tear fluid. Compared to its homologues, cystatin D presents an unusual inhibition profile with a preferential inhibition cathepsin S > cathepsin H > cathepsin L, and no inhibition of cathepsin B or pig legumain. To elucidate the structural reasons for this specificity, we have crystallized recombinant human Arg26-cystatin D and solved its structures at room temperature and at cryo conditions to 2.5 and 1.8 Å resolution, respectively. Human cystatin D presents the typical cystatin fold, with a five-stranded anti-parallel β-sheet wrapped around a five-turn α-helix. The structures reveal differences in the peptidase-interacting regions when compared to other cystatins, providing plausible explanations to the restricted inhibitory specificity of cystatin D for some papain-like peptidases, and its lack of reactivity towards legumain-related enzymes.
INTRODUCTION
residues, of which the first 20 constitute a typical signal peptide (14) . Cystatin D was originally found as the product of a gene segment displaying a high degree of homology to the human cystatin C gene (15) . Its complete amino acid sequence displays 55% identical residues compared to the cystatin C sequence, with all sequence motifs known to be essential for cysteine peptidase inhibition well conserved (14) . However, the inhibition profile of cystatin D for human family C1 peptidases is clearly different from that of, e.g., cystatin C (1, 16) . Unlike the latter, cystatin D is unable to inhibit cathepsin B. Besides it shows a preferential inhibition of cathepsin S over cathepsins H and L (16) . By a site-directed mutagenesis approach to alter residues in the Nterminal segments of cystatin D and C, it has been shown that these residues can interact with the non-primed substrate pockets of the enzymes in a substrate-like manner (17) . Moreover, evidence was presented that N-terminal sequence differences partly explain the specificity differences between cystatins D and C. However, by analysis of engineered hybrid cystatins it was apparent that structural differences also in the frame-work cystatin molecule must have a large effect on the inhibitory specificity of cystatin D (17) .
It was recently reported that some type 2 cystatins can inhibit mammalian legumain, a cysteine peptidase of family C13, through a novel reactive site located on the opposite side to the papain-binding site (18) , in a loop referred to as the back-side loop (BSL). This site results in tight reversible inhibition of pig legumain and is active on human cystatins C, E/M and F, but not on cystatins A, B and D. Thus, also with respect to inhibition of family C13 enzymes, cystatin D displays a more restricted and specific inhibition profile than other type 2 cystatins.
In the present study, we have crystallized and determined the three-dimensional structure of recombinant human cystatin D, with the aim to clarify the structural reasons for its selectivity at target enzyme inhibition. 7 90 mA. Crystals were mounted in a quartz capillary for data collection. A full data set was collected from a single crystal.
Cryo-conditions for data collection were worked out using sucrose as cryo protectant. The crystal was equilibrated with the mother liquor in the presence of 15% sucrose for a few minutes.
The crystal was then mounted in a nylon CryoLoop (Hampton Research) and flash-cooled directly in a cold nitrogen stream at about 100K. Diffraction data were collected at the crystallographic beamline BL711 at the MAX-II synchrotron lab in Lund (Sweden) using a Mar345 image plate detector (X-ray Research GmbH, Norderstedt, Germany). A typical exposure time was 60 s per frame with 1° oscillation. All data sets were processed using the DENZO and SCALEPACK packages (24) .
Structure determination
The structure of cystatin D was solved by molecular replacement methods. For the RT data, this was done by using CEW cystatin 2 as search model. Different modifications, such as poly Ala, poly Ser, were tried. The programs AMoRe (25) and Crystallography & NMR System (CNS) (26) were used for the replacement search of the data between 15.0 and 4.0 Å. The molecular replacement solution was refined using the program CNS on the complete RT data (30.0 to 2.5 Å). The refined RT structure was then used as model for the rigid-body refinement on the cryo data.
Structural alignment and graphical illustrations
Multiple sequence alignment of cystatins with known structures was initially done by the GCG (Genetics Computer Group) Wisconsin Package software. The alignment was modified using the multiple structure alignment obtained with the program MAPS (Multiple Alignment of Protein Structures) 3 . The structures used in the alignment were obtained from the Protein Data Bank (27):
CEW cystatin 2 , dimeric human cystatin C 4 , cystatin A 5 , cystatin B 6 , and oryzacystatin 7 . If not otherwise indicated, the amino acid numbering used is that of human cystatin C 8 , as previously used for cystatin D and other human type 2 cystatins (13, 28, 29) . Graphical representations were prepared with the programs MOLMOL (30) and GRASP (31) .
RESULTS AND DISCUSSION

Crystallization of cystatin D and crystal data collection
Recombinant human cystatin D crystals appeared during the first week in CS-kit 1 condition 39
(100 mM Na-HEPES buffer, pH 7.5, with 2% (w/v) PEG400 and 2 M (NH 4 ) 2 SO 4 ), at 18°C. Finer grids based on this condition were settled at the same temperature by using either Tris or HEPES as buffer at a pH interval between 6.5 and 8.0 and by varying the ammonium sulfate (0.4-2.4 M) and PEG (1-2% (w/v)) concentrations. Crystals were obtained under several conditions. They were stable and presented typical shapes as long rods or plates. Two of the well-diffracting crystals were used for structure determination. These crystals were grown at 18°C in 100 mM
Tris, pH 7.5, with 2.4 M (NH 4 ) 2 SO 4 and 2.5% PEG 400.
A room temperature data set was collected from a plate-shaped crystal with dimensions about 0.5 x 0.3 x 0.1 mm 3 . The crystal diffracted beyond 2.5 Å and a full data set could be collected from a single crystal (Table I) . A second similar crystal soaked in 15% sucrose was used to collect a data set at about 100 K, giving diffraction beyond 1.8 Å (Table I) .
<Table I around here>
Molecular replacement was used as method to solve the structure of cystatin D from the RT data set. This was accomplished using the crystal structure of CEW cystatin as search model.
Using AMoRe (25) and CNS with data collected between 15.0 and 4.0 Å, we obtained the same rotational solutions, which were well above background regardless of which model was used.
From the extinction list, two axes were clearly shown as screw axes. Thus, the space groups density was detected for the residues in the N-terminal segment before Ala10 (Fig. 1A ). This region must thus be disordered in structure. The flexible region around residues 80-84 was difficult to build in before the composite-omit-maps were made. Thirty-two water molecules
were added to the model where strong difference densities (>3σ) were shown and the hydrogenbond geometry was good. The individual B-factor refinement was applied to the final RT model.
The structure solution was straightforward for the cryo data after the RT structure was refined. The cryo structure had slight but significant changes in the cell dimensions (Table I) . The refined RT model was then used for the rigid-body refinement on the cryo data in the resolution range from 30.0 to 1.8 Å. It was trivial to perform the subsequent refinement steps by CNS and to add a total of 85 water molecules to the cryo model (Table I) .
Despite the significant unit cell changes, particularly on the length of b-axis, the RT and cryo The strong similarity between the RT and cryo structures can also be seen from a B-factor plot (web figure).
Overall structure
Human cystatin D adopts the so-called 'cystatin fold' (Fig. 1B) , as its five homologues with known structures (7, 8, 10, 11) . The core structure is built from a five-stranded antiparallel β-sheet
Lys109-Lys119) that is wrapped around a five-turn α-helix (Lys21-Lys36) (Figs. 1B, 2). Comparison of the electrostatic potential surfaces of the two proteins ( Fig. 1E ) revealed further differences. Cystatin D has a narrower and more elongated shape than CEW cystatin. This might be a result of the missing bulge in the β2 strand, straightening up the β-sheet in cystatin D.
Also, the two cystatins differ quite significantly with respect to the charge distribution on their surfaces. In CEW cystatin, positive and negative charges are evenly distributed on the protein surface. In cystatin D, however, the surface presents some strongly (mainly negatively) charged areas whereas other areas are pronounced hydrophobic.
Human cystatin D is present in two natural forms due to a gene polymorphism (19) . It has been shown that this variation neither significantly affects the enzyme-binding properties of the inhibitor nor has drastic effects on protein stability (16) (13) is Arg, has a population frequency of 0.45 (19) . As the predicted amino acid sequence of mature cystatin D is one residue longer in the N-terminal than the reference sequence of cystatin C 8 , the polymorphic residue is number 25 in an alignment of cystatin sequences (Fig. 2) . The other natural form of human cystatin D (population frequency of 0.55) has Cys in this position unlike other type 2 cystatins, for which Arg25 is well conserved (Fig. 2 ). The present structure shows that the Arg25 residue in cystatin D is situated in the second turn of the α-helix. Although it seems to be exposed at the surface of the protein, its side-chain is undoubtly oriented towards the cavity formed by the bent L2 loop, as revealed by the density map. The side-chain is likely 'trapped' by a salt bridge with the side-chain of either Glu103 or Asp108 in the proximity of the L2 loop. The electron density for the amine groups further out in the side-chain of Arg25 is weak or almost absent in both the cryo and the RT structures. This indicates a large flexibility in the conformation of these amine groups, reflected by high B-factor values, suggesting that they can alternate between the two anchoring sites formed by Glu103 and Asp108. Similarly, the conserved Arg residue in CEW cystatin seems to form a hydrogen bond with the Ser residue in position 103 (Ser101 in CEW cystatin numbering). By homology, the conserved Arg25 residue in the type 2 cystatins S, SA and SN could also form a salt bridge with Glu103 or Glu108 found in their sequences. The Arg25 residue thus appears to be an important factor for stabilization of the α-helix of some type 2 cystatins. In the cystatin D variant with Cys as residue 25, the bridge between the α-helix and the L2 loop cannot be formed and its stabilizing feature would be lost. This could be an explanation to the fact that the Cys variant is connected to both lower expression yields in E. coli and lower purification yields from saliva than the Arg variant (16) . As pointed out by Balbin et al., the unpaired Cys residue may be involved in disulfide exchange with other proteins in saliva (16) .
The present results demonstrate that the Cys side-chain with its thiol group indeed could be exposed to allow this.
<Fig. 1 around here> <Fig. 2 around here>
The binding site for papain-like peptidases
The papain-binding site in cystatins is constituted by three well conserved segments: the flexible N-terminal part, a hairpin loop in the central region (L1) and another towards the C-terminal end (L2) of the sequence (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) . These segments form a tripartite wedge-shaped edge (7, 8, 10, 11, 43) that enters the catalytic site in a substrate-like manner (10, 44) . In the cystatin D structure, the papain-binding segments are located in such a tripartite wedge ( Fig. 1) in accordance with the other cystatin structures.
The density map for the N-terminal segment in cystatin D is poorly defined and, therefore, the structure model gives little information about the potential for interactions between the Nterminal segment of this cystatin and target family C1 peptidases. In the RT model, the first residue for which clear electron density is shown is Ala10. In the cryo model for cystatin D, this residue is Gly11. In the structures of CEW cystatin and human cystatin C, the first residues with clear density are Gly11 (Gly9 in CEW cystatin numbering) and Val10, respectively (7, 12) . This highlights a similar, very flexible N-terminal segment in all type 2 cystatins. For the other parts of the potential papain-binding site, there are some relevant differences in the cystatin D structure compared to that of CEW cystatin, however.
<Fig. 3 around here>
The L1 loop of the binding site contains the conserved 'cystatin motif', QXVXG, and is located between strands β2 and β3. L1 in cystatin D is larger and adopts a more 'squared' form than in CEW cystatin (Fig. 3A) . This broader loop is a consequence of the missing β-bulge around position 49 in the β2 strand. This bulge is present in all cystatin structures solved so far,
i.e., in CEW cystatin, human cystatins C, A and B, as well as in the plant cystatin, oryzacystatin.
The missing bulge causes a displacement of one amino acid residue in the β2 strand of cystatin D, when comparing the sequence-based alignments of earlier publications (29) to the threedimensional structure alignment based on the present results (Fig. 2) . Both alignments come in tune again after Gly59, at the end of the papain-binding 'cystatin motif'. Thus, the extra residue is placed in the L1 loop, changing its morphology (Fig. 3A) .
The L2 loop of the binding site is, as for CEW cystatin, a five-residue long hairpin loop between strands β4 and β5. The L2 appears to be more bent over the α-helix than in the crystal structure of CEW cystatin (Fig. 3B ). This causes a deviation of approximately 30 degrees of the side chains of Pro105 and Trp106 from the wedge-shaped edge formed by the three segments in CEW cystatin.
From the electrostatic point of view, the charge distribution on the papain-binding site (Nterm, L1 and L2) of CEW cystatin is completely hydrophobic. In cystatin D, however, the very negative charges of Glu107 and Asp108 in L2 (Fig. 1E) This results in lost contacts between the other cystatin parts involved in enzyme binding and the peptidase and, consequently, decreases the papain affinity of cystatin D compared to CEW cystatin and human cystatin C (1). Moreover, even if L1 would not be as protruding as it is, the more bent L2 might not be able to make as many contacts with papain as expected by analogy to other cystatins' mode of enzyme binding.
Previous studies have shown that a truncated form of human cystatin C, lacking the first ten residues of the N-terminal segment, has three orders of magnitude lower affinity for papain and other family C1 peptidases than full-length cystatin C (34, 38) . The same large decrease in target enzyme affinity is observed for its W106G variant (39) . The affinity of cystatin D for papain (K i 1.9 nM; reviewed in ref. (1)) is five orders of magnitude lower than that observed for wildtype cystatin C. These kinetic data suggest that sterical hindrances due to the larger L1 loop of cystatin D destabilize not only contacts in this region but also in the N-terminal region and/or in the L2 loop. In addition, the bent L2 loop most likely disfavors interactions between the imidazole rings in the inhibitor (Trp106) and the enzyme (Trp177 and Trp181).
Likewise, we 'docked' the structures of cystatin D and cathepsin B 9 , again using the complex between cystatin B and papain as starting point for the model. Contrary to the inhibition of papain by cystatins, cathepsin B is inhibited in a two-step kinetic reaction (45) . As proposed should fit well into the pocket.
The putative binding site for legumain-like peptidases
As recently reported, some type 2 cystatins are able to inhibit mammalian legumain (18), a lysosomal cysteine endopeptidase of family C13 (46) , which shows preference for hydrolysis after an asparaginyl bond (47) . The 'back-side loop' (BSL) at the end of the main α-helix ( Fig   1A, B) , containing residue Asn39, was identified as most likely being directly involved in legumain inhibition by these cystatins. In effect, Asn39 could be responsible for an inhibitory mechanism where cystatins inhibit mammalian legumain in a substrate-like manner (18) . Like the inhibitorily active cystatins identified so far, human cystatins C, E/M and F, CEW cystatin and Bm-CPI-2, a type 2 cystatin homologue from the filarial nematode parasite Brugia malayi 10 , cystatin D presents an asparagine residue in this loop (Fig. 1, 2, 4) . Still so, cystatin D is the only human type 2 cystatin investigated that cannot inhibit mammalian legumain (18) . Assuming that Asn39 in other type 2 cystatins indeed is directly involved in legumain inhibition, we examined and compared the structures in the BSLs of cystatin D and CEW cystatin (Fig. 4) , the latter being a tight-binding inhibitor of pig legumain (48) . This was done in the attempt to provide a plausible explanation to why cystatin D is inactive as a legumain inhibitor.
For cystatin D, the structural differences observed were as follows: 1) The Asn residue in cystatin D is neither structurally conserved nor accessible at the surface of the protein. Instead, it is located at a position corresponding to residue 38 in the other type 2 cystatin structures (residue 36 in CEW cystatin) (Fig. 4A) . Its side-chain points towards the core of the protein and is strongly hydrogen-bonded to Lys75 at the end of the third β-strand. polypeptides (49, 50) . It is tempting to speculate that cystatin D acts as a physiological inhibitor of these or similar enzymes in saliva and hence could have a biological function to inhibit the growth and action of pathogenic oral bacteria.
<Fig. 4 around here>
Conclusions
In the present study, we have determined the structure of recombinant human cystatin D by X-ray crystallography under both RT and cryo conditions (2.5 and 1.8 Å resolution, respectively).
This type 2 cystatin is not as widely distributed in the body as its homologue, cystatin C, but is rather restricted to saliva and tear fluid (13) . This may point to a more restricted biological function of cystatin D than that of a general protector against papain-like lysosomal peptidases being released from, e.g., tumor cells or leaking from dying cells, as has been suggested for cystatin C. Besides, while cystatin C is considered as an 'universal' inhibitor, displaying inhibitory activity against all family C1 peptidases studied without relevant specificity, cystatin D shows a much more restricted inhibition profile with affinity for cathepsin S > cathepsin H > cathepsin L, and no inhibition of cathepsin B or pig legumain in family C13 (16, 18) . This restricted inhibition profile makes cystatin D a good target for structure-function studies aiming at an understanding of factors determining the inhibitory specificity of cystatins.
The crystal structures of cystatin D reveal no exceptional overall differences between this cystatin and its homologues. The 'cystatin fold' is rather well conserved, leaving the major structural differences to the most flexible parts of the protein, i.e., the peptidase-binding sites. Human cystatin C amino acid numbering was used with the letter "a" indicating residues inserted in the cystatin D structure compared to the other cystatins structures. The residues closest in space at structural alignment are aligned in this figure, but it should be noted that structural positions of cystatin D residues 37-37a-38 all deviate quite much from those for residues 37-38 in CEW cystatin and human cystatin C. Which of the three cystatin D residues that should be seen as the inserted one could therefore not be predicted with certainty (see Fig. 4 ). Similarly, in the larger L1 loop of cystatin D, residues 57a-58 correspond to residue 58 of the other two type 2 cystatins, with the latter located in a position intermediate to those of cystatin D residues 57a and 58 (see Fig. 3 ). 
